Drug Patent Expirations in December 2013

Drug Patent Expirations for December 2013

Tradename Applicant Generic Name Patent Number Patent Expiration
EMADINE Alcon emedastine difumarate 5,441,958 Dec 8, 2013
ENTEREG Cubist Pharms alvimopan 5,434,171 Dec 8, 2013
EDARBYCLOR Arbor Pharms Llc azilsartan kamedoxomil; chlorthalidone 5,583,141 Dec 10, 2013
SOLAGE Aqua Pharms mequinol; tretinoin 5,194,247 Dec 10, 2013
EDARBI Arbor Pharms Llc azilsartan kamedoxomil 5,583,141 Dec 10, 2013
CYMBALTA Lilly duloxetine hydrochloride 5,023,269*PED Dec 11, 2013
ABREVA Glaxosmithkline docosanol 5,534,554 Dec 13, 2013
LUPRON DEPOT-PED Abbvie Endocrine Inc leuprolide acetate 6,036,976 Dec 13, 2013
FROVA Endo Pharms frovatriptan succinate 5,962,501 Dec 16, 2013
MYLOTARG Wyeth Pharms Inc gemtuzumab ozogamicin 5,585,089 Dec 17, 2013
AGENERASE Glaxosmithkline amprenavir 5,585,397 Dec 17, 2013
DEFINITY Lantheus Medcl perflutren 5,585,112 Dec 17, 2013
AEROSPAN HFA Acton Pharms flunisolide 5,980,867 Dec 20, 2013
DDAVP Sanofi Aventis Us desmopressin acetate 5,674,850 Dec 23, 2013
DDAVP (NEEDS NO REFRIGERATION) Sanofi Aventis Us desmopressin acetate 5,674,850 Dec 23, 2013
VIOXX Merck rofecoxib 6,239,173*PED Dec 24, 2013
VIOXX Merck rofecoxib 5,474,995*PED Dec 24, 2013
ANTHELIOS SX Loreal Usa avobenzone; ecamsule; octocrylene 5,587,150 Dec 24, 2013
EFFEXOR XR Wyeth Pharms Inc venlafaxine hydrochloride 5,916,923*PED Dec 28, 2013
EFFEXOR XR Wyeth Pharms Inc venlafaxine hydrochloride 6,444,708*PED Dec 28, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Comments are closed.